Alkem Laboratories Ltd (ALKEM) Stock Analysis: Valuation, Latest Results, Financial Ratios & DeciZen Rating

BSE: 539523 | NSE: ALKEM | Pharmaceuticals & Drugs | Mid Cap

Alkem Laboratories Share Price

5,666.50 54.85 0.98%
as on 05-Dec'25 09:52

Alkem Laboratories Ltd (ALKEM) Stock Analysis: Valuation, Latest Results, Financial Ratios & DeciZen Rating

BSE: 539523 | NSE: ALKEM | Pharmaceuticals & Drugs | Mid Cap

DeciZen - make an informed investing decision on Alkem Laboratories

Based on:

Overall Rating
Login to view analysis. Bole Toh

1. Quality


Login to view analysis.

2. Valuation


Login to view analysis.

3. Price Trend


Login to view analysis.

Alkem Laboratories stock performance -

Key Ratios
mw4me loader
P/E Ratio (SA):
29.85
Market Cap:
67,095.7 Cr.
52-wk low:
4,498.9
52-wk high:
5,867.5

Is Alkem Laboratories Ltd an attractive stock to invest in?


Login to view analysis.

10 Year X-Ray of Alkem Laboratories: Login to view analysis.

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Alkem Laboratories Ltd has performed well in majority of the past ten years indicating its past ten year financial track record is very good

Value Creation

Value Creation Index Colour Code Guide

Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25TTM
ROCE % 21.9%21%19%17.1%20.5%23.4%18%13.2%15.2%19.7%-
Value Creation
Index
0.60.90.70.50.81.10.60.20.40.8-

Growth Parameters

Growth Parameters Colour Code Guide

Sales 3,8594,5485,2815,7146,6777,2208,8309,0557,9648,8139,246
Sales YoY Gr.-17.9%16.1%8.2%16.9%8.1%22.3%2.6%-12.1%10.7%-
Adj EPS 59.273.860.365.7104.5138126.893.1132.2170.9188
YoY Gr.-24.7%-18.3%9%59%32%-8.1%-26.6%42%29.2%-
BVPS (₹) 301.1367.4408.7457.2525.3637.9731.4782.1882.91,030.71,142.9
Adj Net
Profit
7088837217861,2501,6501,5161,1131,5812,0432,248
Cash Flow from Ops. 6304993187456821,3241,2991,4371,6872,189-
Debt/CF from Ops. 0.60.71.70.71.811.70.80.60.2-

CAGR

CAGR Colour Code Guide

9 Years 5 Years 3 Years 1 Years
Sales 9.6%5.7%-0.1%10.7%
Adj EPS 12.5%10.3%10.5%29.2%
BVPS14.7%14.4%12.1%16.7%
Share Price - 14.7% 22.1% 0.4%

Key Financial Parameters

Performance Ratio Colour Code Guide

Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25TTM
Return on
Equity %
21.122.115.515.221.323.718.512.315.917.917.3
Op. Profit
Mgn %
1919.318.918.422.22720.515.32124.525.4
Net Profit
Mgn %
18.419.413.713.818.722.917.212.319.923.224.3
Debt to
Equity
0.10.10.10.10.20.20.30.10.100
Working Cap
Days
180155162159156175178184255264148
Cash Conv.
Cycle
4141455162768081754694

Recent Performance Summary

Login to view analysis.
Login to view analysis.

Latest Financials - Alkem Laboratories Ltd.

Standalone Consolidated
TTM EPS (₹) 188 197.5
TTM Sales (₹ Cr.) 9,246 13,890
BVPS (₹.) 1,142.9 1,116.2
Reserves (₹ Cr.) 13,641 13,322
P/BV 4.91 5.03
PE 29.85 28.42
From the Market
52 Week Low / High (₹) 4498.90 / 5867.50
All Time Low / High (₹) 1175.00 / 6440.00
Market Cap (₹ Cr.) 67,096
Equity (₹ Cr.) 23.9
Face Value (₹) 2
Industry PE 40.7

Management X-Ray of Alkem Laboratories:

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *0.000.000.000.000.000.000.000.000.000.00
* Pledged shares as % of Promoter's holding (%)

Valuation of Alkem Laboratories - Standalone Basis

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

mw4me loader

Event Update

Login/Register to view analysis.

Analyst's Notes

data not found
No data found!

Key Ratios of Alkem Laboratories

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)
PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25
Sales3,8594,5485,2815,7146,6777,2208,8309,0557,9648,813
Operating Expenses 3,1393,6704,3084,6685,2095,2717,0197,6786,2936,657
Manufacturing Costs4956546866517047371,081951883986
Material Costs1,2811,4381,7391,9912,2292,3083,0143,3672,0802,257
Employee Cost 6277228629601,0671,1591,4341,5161,4781,631
Other Costs 7358551,0211,0671,2091,0661,4901,8431,8521,784
Operating Profit 7208789731,0461,4681,9491,8101,3771,6712,156
Operating Profit Margin (%) 18.7%19.3%18.4%18.3%22.0%27.0%20.5%15.2%21.0%24.5%
Other Income 2511171016896190200266306507
Interest 59243228394338868076
Depreciation 7476108141187199219230239284
Exceptional Items 00000-1300-640
Profit Before Tax 8398949349441,3381,8841,7531,3271,5942,304
Tax 139112181447419921219334214
Profit After Tax 7008837168001,2641,6851,5411,1341,5612,090
PAT Margin (%) 18.1%19.4%13.6%14.0%18.9%23.3%17.5%12.5%19.6%23.7%
Adjusted EPS (₹)58.673.959.966.9105.8141.0128.994.9130.5174.8
Dividend Payout Ratio (%)22%20%22%24%24%21%26%53%31%26%

Balance Sheet

(All Figures are in Crores.)
PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25

Equity and Liabilities

Shareholders Fund 3,6004,3934,8855,4656,2807,6268,7449,35010,55512,322
Share Capital 24242424242424242424
Reserves 3,5764,3694,8615,4416,2577,6028,7209,32610,53112,298
Minority Interest0000000000
Debt3513685485031,2091,3332,2461,126957371
Long Term Debt0066600000
Short Term Debt3513685414971,2031,3332,2461,126957371
Trade Payables4676858197548129531,1111,0761,5711,464
Others Liabilities -4-139-15-67-15-932094-33210
Total Liabilities 4,4135,3076,2366,6568,2879,81812,12011,64612,75114,166

Fixed Assets

Gross Block9451,2631,7141,9732,3522,4572,8272,9323,1443,083
Accumulated Depreciation701372433675156999451,1071,3621,492
Net Fixed Assets 8751,1261,4711,6061,8371,7581,8821,8251,7821,591
CWIP 1472182993823143232322299177
Investments 1,1581,5181,5451,6961,9562,1522,5293,0062,8294,407
Inventories5908591,0249911,0931,5131,9761,7251,8501,523
Trade Receivables4806338759671,5551,5571,7681,7681,7541,560
Cash Equivalents 5241992783987661,6732,2972,1641,0661,056
Others Assets 6407557446167678411,4369303,3803,953
Total Assets 4,4135,3076,2366,6568,2879,81812,12011,64612,75114,166

Cash Flow

(All Figures are in Crores.)
PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25
Cash Flow From Operating Activity 6304993187456821,3241,2991,4371,6872,189
PBT 8398949349441,3381,8841,7531,3271,8812,597
Adjustment -65-477130141123108129212-51
Changes in Working Capital 3-187-512-124-564-362-227206-5340
Tax Paid -147-205-181-205-234-321-335-224-353-397
Cash Flow From Investing Activity 311-362-273-313-995-1,121-1,669197-866-1,007
Capex -167-452-493-353-267-95-234-139-100-186
Net Investments 386195268175-448-916-1,123483-962-691
Others 92-105-48-135-280-111-312-147196-130
Cash Flow From Financing Activity -958-125-60-276173-209437-1,711-959-1,037
Net Proceeds from Shares 0000000000
Net Proceeds from Borrowing -26-306-0000000
Interest Paid -53-24-32-28-39-38-26-70-62-56
Dividend Paid -152-72-179-179-359-335-418-526-538-502
Others -7270145-68570163881-1,116-359-478
Net Cash Flow -1813-15156-141-567-77-138145

Finance Ratio

PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25
Ratios
ROE (%)20.922.115.4315.4521.5324.2318.8312.5415.6818.27
ROCE (%)21.9421.0118.9717.0520.4623.4317.9613.1715.2319.66
Asset Turnover Ratio0.850.960.960.930.930.840.850.80.670.67
PAT to CFO Conversion(x)0.90.570.440.930.540.790.841.271.081.05
Working Capital Days
Receivable Days40445056667565687967
Inventory Days53576262546369718068
Payable Days116146158144128140125119232245

Alkem Laboratories Ltd Stock News

Alkem Laboratories Ltd FAQs

The current trading price of Alkem Laboratories on 05-Dec-2025 09:52 is ₹5,666.5.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 04-Dec-2025 the market cap of Alkem Laboratories stood at ₹67,095.7.
The latest P/E ratio of Alkem Laboratories as of 04-Dec-2025 is 29.85.
The latest P/B ratio of Alkem Laboratories as of 04-Dec-2025 is 4.91.
The 52-week high of Alkem Laboratories is ₹5,867.5 and the 52-week low is ₹4,498.9.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Alkem Laboratories is ₹9,246 ( Cr.) .

About Alkem Laboratories Ltd

Alkem Laboratories is one of India’s largest generic and specialty pharmaceutical company. Also, it has consistently been ranked amongst the top ten pharmaceutical companies in India. Its portfolio includes illustrious brands like Clavam, Pan, Pan-D and Taxim-O, which feature amongst top 50 pharmaceutical brands in India. For over a decade, its dominance in anti-infective segment has remained unchallenged. Some part of its revenue is generated via offshore sales. The company has manufacturing facilities at multiple locations in India and the United States of America. Its upper-crest facilities are inspected and audited as per cGMP guidelines as laid down by leading regulatory authorities such as USFDA, MHRA - UK, SAHPRA-South Africa, TGA - Australia, ANVISA - Brazil, WHO - Geneva, TPD - Health Canada, PPB - Kenya, NDA - Uganda, MOH - Sudan, INVIMA - Colombia, TFDA - Tanzania, Zimbabwe, BfArM-Germany & Other Africa, Asian & CIS Countries.

Business area of the company

The company is one of India’s foremost global pharmaceutical company. The company is engaged in the development, manufacture and marketing of pharmaceuticals with operational footprints across different countries. In India, it has a formidable presence in several therapy segments and consistently features amongst the top ten pharmaceutical companies. Steered by its industry experience of over four decades, it offers high-quality branded generics, generic drugs, active pharmaceutical ingredients and nutraceuticals.

Awards and Recognition

2016:

  • Won the 'HR Tech Award for Best use of Technology in Human Resources' by World HRD Congress.
  • Won the Best Demand Planning and Forecasting Company - Pharmaceutical by ISCM's - SCMPro's in Demand Planning and Forecasting Forum Awards 2016.
  • Alkem-Pentacare division won the most enterprising company in leveraging technology in use of Mobile Applications by DigiPharmaX.
  • Brand 'Pan' received ‘Brand of the Year' award in sub-chronic category at AWACS Awards, 2016.
  • Alkem won the Guinness World Record for creating largest Blister Pack Mosiac at RSSDI Hyderabad.

2017:

  • Alkem Corporate Video won the 1st runners up award in the Best Corporate Film for driving Employee Engagement initiatives in the Mega Corporate Film Festival and Awards held in Mumbai.
  • Received the Best Stand-out IR award 2017 by IR Society India in association with KPMG and Bloomberg.
  • Won the People Matters league Awards - Learning & Development 2017 - Best in Cultural Transformation in Mumbai.
  • Won the Guinness world Records for creating largest Bindi Mosiac at RSSDI Bhubaneswar.
  • Won the Rising Digital Star of the Year for various digital initiatives by DigiPharmaX Awards 2017.

2018:

  • Best Innovative CSR Project at CSR Summit & Awards 2018.
  • Brand ‘Clavam’ received Brand of the Year 2018 Award at AWACS Awards for marketing excellence.
  • Business Excellence Award 2018 for Best Range of ICU Products, Pharma and Health Care Summit organized by CIMS (Current Index of Medical Specialties).

2019:

  • Express Pharma Excellence Award at Pharma CXO Summit 2011.
  • Best Use of Technology in Sales Hiring by Global Eminence Digital Awards sponsored by AQUILAA.

2020:

  • CIO Conclave and Awards 2020 in the category ‘Best IT Team of the year’.
  • Alkem Laboratories as Great Place to Work-Certified organization in the large organization category across industries.
  • India's Best Workplaces in Biotechnology & Pharmaceuticals.

Milestones

  • 1973: Inception of Alkem Laboratories.
  • 1978: First manufacturing unit was established at Taloja near Mumbai.
  • 1992: Second manufacturing facility established at Mandva, Gujarat which was converted into an API facility in 2005.
  • 2003: First research and development facility established at Taloja.
  • 2006: Taxim became India’s first anti-infective drug to surpass annual sales figure of ` 1,000 million in the domestic market.
  • 2007: Filed the first ANDA in the United States for the drug Amlodipine.
  • 2009: Received the first ANDA approval in the United States for the drug Amlodipine.
  • 2009: Acquired Pharmacor Pty. Ltd., a generic pharmaceutical company in Australia.
  • 2010: Acquired Ascend Laboratories, pharmaceutical company in the United States.
  • 2011: Acquired Enzene, a company engaged in the development of biosimilars in India.
  • 2012: Acquired an API manufacturing facility in the United States.
  • 2014: Acquired the ‘Clindac-A’ brand in India from Galderma S.A.
  • 2014: Clavam surpassed Rs 2,000 million domestic sales figure.
  • 2015: Acquired a formulation manufacturing facility in the United States.
  • 2015: Successfully completed Initial Public Offering (IPO).
  • 2018: Revenue from the US market crossed $ 200 million in annual sales.
  • 2019: Crossed the revenue milestone of $1 billion.
To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×